TRVI
Trevi Therapeutics Inc

1,778
Mkt Cap
$1.34B
Volume
991,322.00
52W High
$11.83
52W Low
$2.36
PE Ratio
-26.17
TRVI Fundamentals
Price
$10.80
Prev Close
$11.01
Open
$11.00
50D MA
$9.45
Beta
0.64
Avg. Volume
1.59M
EPS (Annual)
-$0.4698
P/B
6.75
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Y Intercept Hong Kong Ltd Takes $475,000 Position in Trevi Therapeutics, Inc. $TRVI
Y Intercept Hong Kong Ltd acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a...
PR Newswire·2d ago
News Placeholder
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference PR Newswire NEW HAVEN, Conn., Nov. 4, 2025 Fireside Chat...
PR Newswire·4d ago
News Placeholder
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·4mo ago
News Placeholder
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
Zacks·6mo ago
News Placeholder
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics Completes Enrollment for Phase 2b CORAL...
PR Newswire·9mo ago
News Placeholder
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
Trevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire NEW HAVEN, Conn., Jan. 30, 2025 NEW...
PR Newswire·9mo ago
News Placeholder
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics Announces Company...
PR Newswire·10mo ago
News Placeholder
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering PR Newswire NEW HAVEN, Conn., Dec. 16, 2024 NEW...
PR Newswire·11mo ago
News Placeholder
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%
An independent statistician confirmed the sample size following a re-estimation analysis, ensuring that the trial’s design remains statistically robust.
Stocktwits·11mo ago

Latest TRVI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.